ClinPhone shows commitment to Good Clinical Practice by completing the latest Medicines and Healthcare Products Regulatory Agency inspection.
Nottingham, UK-June 2, 2008-ClinPhone (www.clinphone.com), a Clinical Technology Organization (CTO), has received the GCP Inspection Statement to complete the latest Inspection by the GCP Inspectorate of the Medicines and Healthcare Products Regulatory Agency (MHRA).
The MHRA is an executive agency of the Department of Health and was established in April 2003 from a merger between the Medicines Control Agency and the Medical Devices Agency. The agency is responsible for ensuring that medicines and medical devices work and are acceptably safe.
As with any organization involved in the clinical trials process, ClinPhone has implemented rigorous procedures to ensure compliance with Good Clinical Practice (GCP). These are assessed by clients, who conduct in excess of 40 audits per year at ClinPhone, as well as by Regulatory Authorities.
In the UK, ClinPhone is subject to inspection by the MHRA, in accordance with ‘The Medicines for Human Use (Clinical Trials) Regulations’ (Statutory Instruments 2004/1031 as amended). ClinPhone underwent their second routine GCP Inspection in mid-November 2007. Following submission of responses to the Inspection Report, a revised GCP Inspection Statement, signifying the completion of the latest inspection cycle, was received on 23rd April 2008.
Steve Kent, chief executive officer of ClinPhone, comments, “This reinforces to our clients that ClinPhone are fully committed to Good Clinical Practice. We have the appropriate policies and procedures in place, as well as robust technology with sufficient back-up systems, to successfully manage our clients’ studies to the very highest standards.”
To find out more about the Medicines and Healthcare Products Regulatory Agency (MHRA), please visit: www.mhra.gov.uk/aboutus/index.htm.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.